Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Patent metadata

Field	Value
Publication number	US-9993539-B2
Application number	US-201715637906-A
Country	US
Kind code	B2
Filing date	Jun 29, 2017
Priority date	Aug 5, 2015
Publication date	Jun 12, 2018
Grant date	Jun 12, 2018

Abstract

A method of treating a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, BRCA, melanoma, and/or uterine cancer.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that aberrantly express a peptide in the patient, wherein said peptide consists of the amino acid sequence of SMLGEEIQL (SEQ ID NO: 2), wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , further comprising expanding T cells in vitro.

6. The method of claim 1 , wherein the peptide is in a complex with an MHC molecule.

7. The method of claim 1 , wherein the composition further comprises an adjuvant.

8. The method of claim 7 , wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG) and virosomes.

9. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

10. The method of claim 9 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

11. The method of claim 1 , further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells.

12. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.

13. The method of claim 1 , wherein the contacting T cells with an antigen presenting cell is in vitro.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Mueller Phillip
• Leibold Julia
• Goldfinger Valentina

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57575

  involving oncogenic proteins · CPC title

• C12Q2600/16

  Primer sets for multiplex assays · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title